Abstract:Purpose: to study long-term results of anti-VEGF therapy for macular diseases of patients followed up for 60 months in real clinical practice. Materials and methods. The research group included 57 patients (43 women, 14 men; median age 62 years) who received antiVEGF therapy (ranibizumab, aflibercept) and remained under regular observation for 60 months. Of these, 24 patients had “wet” agerelated macular degeneration (wAMD), 20 had myopic choroidal neovascularization (mCNV), 10 had macular edema due to retinal vein occlusions (MERVO), and 3 patients had diabetic macular edema (DME). Statistical analysis of demographic indicators and treatment results was carried out using STATISTICA 13.3 software: conditions of normality for variables, nonparametric and parametric criteria were determined, and rank analysis of variance was carried out. The characteristics of the study group are given in the first part of this article [ROJ, 2022; 15 (3): 11–17]. Results. Over the research period, the best corrected visual acuity (BCVA) increased from 0.29 0.35 0.42 to 0.47 0.54 0.61 (p < 0.00001); 91.2 % of patients maintained the indicator or improved it with regard to the baseline. The proportion of subjects with BCVA ≥ 0.5 ranged from 61.4 to 73.7 % during the research period. The average number of intravitreal injections (IVI) received by the patients was 8.93 10.84 12.75 . We revealed a tendency towards a gradual decrease in the intensity of treatment and confirmed it (p < 0.00001). The proportion of patients who received 4 IVI or more over 12 months of treatment decreased from 57.9 % in the first year to 12.3 % in the fifth year, and the proportion of cases where anti-VEGF therapy did not need to be resumed before the end of the year of treatment increased from 28.1 % (in the second year of research) to 49.1 % (in the fifth year). The need for IVI anti-VEGF drugs in wAMD and DME was significantly greater than in MERVO and mCNV. Conclusion. The results confirm high efficiency of anti-VEGF therapy. To solve the issue of ill-timed or insufficient treatment, it is necessary to start the therapy as early as possible, use the most effective (proactive) regimens, apply individualized approach to the treatment, take organizational measures aimed at facilitation of access to specialized care, and, generally, to change the attitude of the professional community.

Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept

Long-term Incidence and Risk Factors of Macular Fibrosis, Macular Atrophy, and Macular Hole in Eyes with Myopic Neovascularization

Topographical Quantification of Retinal Fluid in Type 3 MNV and Associations With Short-Term Visual Outcomes

Psychophysical, electrofunctional, and morphological evaluation in naïve neovascular AMD patients treated with intravitreal anti-VEGF

Effect of baseline fluid localization on visual acuity and prognosis in type 1 macular neovascularization treated with anti-VEGF

Long-term results of treatment of neovascular age-related macular degeneration using antiangiogenic drugs: A review of the literature

Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POOR VISUAL ACUITY

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Incidence and Risk Factors of Visual Impairment in Patients with Angioid Streaks and Macular Neovascularization

Functional and structural characteristics in patients with type 3 macular neovascularisation treated with anti-VEGF. Three-year results in real world settings

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1

Long-term Outcome of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Bevacizumab or Ranibizumab As Primary Treatment for Subfoveal Myopic Choroidal Neovascularization

Two-year outcomes of intravitreal ziv-aflibercept

Aflibercept for central retinal vein occlusions: long-term outcomes of a 'Treat-and-Extend' regimen

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 2.

Association Between Subfoveal Choroidal Thickness And Prognoses After Anti-Vascular Endothelial Growth Factor Therapy In Myopic Choroidal Neovascularization

Differences between pathologic and non-pathologic high myopia in 4-year outcomes of anti-VEGF therapy for macular neovascularization

Naïve subretinal haemorrhage due to neovascular age-related macular degeneration. pneumatic displacement, subretinal air, and tissue plasminogen activator: subretinal vs intravitreal aflibercept-the native study

Progression of macular retinoschisis following intravitreal aflibercept injection for myopic macular neovascularization—a case report and review of literature

Choroidal remodeling following different anti-VEGF therapies in neovascular AMD